Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has launched ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, ZetaOmics is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. This development represents a significant step forward in the application of artificial intelligence to cancer research, potentially accelerating the discovery of biomarkers and therapeutic targets.
Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations. This move could open new revenue streams for the company and broaden the impact of its AI technology across the biomedical research community.
For more details, see the full press release at https://ibn.fm/9sIIl.
Lantern Pharma Inc. is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma. withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform, representing a new revenue stream for the company.
The launch of ZetaOmics underscores the growing trend of using AI to streamline and enhance biomedical research. By automating complex bioinformatics tasks and ensuring analytical rigor, the platform could help researchers uncover insights more efficiently and reliably. This is particularly important in oncology, where multi-omic data integration is crucial for understanding cancer biology and developing personalized treatments.
As Lantern Pharma expands its AI capabilities, the company is well-positioned to contribute to the broader precision oncology landscape. The subscription-based model for withZeta.ai also suggests a strategic shift towards recurring revenue, which could provide financial stability and support ongoing research and development efforts.
